Involvement of kallikrein in the antihypertensive response to furosemide in essential hypertension

Journal of Cardiovascular Pharmacology

Volumn 3, Issue 1, 1981, Pages 161-167

  Olshan, Arthur R ^a   O'Connor, Daniel T ^a   Preston, Richard A ^a   Frigon, Ronald P ^a   Stone, Richard A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood volume; Furosemide; Hypertension; Kallikrein; Renal hemodynamics

Indexed keywords

ALDOSTERONE H 3; ANTIHYPERTENSIVE AGENT; FUROSEMIDE; KALLIKREIN; PLACEBO; RADIOISOTOPE; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG THERAPY; ESSENTIAL HYPERTENSION; HUMAN; KIDNEY; KIDNEY BLOOD FLOW; RANDOMIZED CONTROLLED TRIAL; THERAPY;

ALDOSTERONE; FUROSEMIDE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; KALLIKREINS; KIDNEY; MALE; MIDDLE AGED; POSTURE; REGIONAL BLOOD FLOW; RENIN;

EID: 0019380012     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/00005344-198101000-00014     Document Type: Article

References (28)

1. Anderson J, Godfrey BE. Hill DM. Munro-Faure AD. Sheldon J: A comparison of the effects of hydrochlorothiazide and of furosemide in the treatment of hypertensive patients. Q J Med 40:541-560. 1971
2. Finnerty FA Jr. Maxwell MH. Lann J. Moser M: Long-term effects of furosemide and hydrochlorothiazide in patients with essential hypertension. Anaioloay 28:125-133. 1977
3. Mroczek WJ. Davidov M, Finnerty FA: Large dose furosemide for hypertension. Am J Cardiol 33:546-549. 1974
4. Dikshit K. Vyden JK. Forrester JS. Chatterjee K. Prakash R. Swan HJC: Effects of furosemide in congestive heart failure after acute myocardial infarction. N Engl J Med 288:1087-1090. 1973
5. Conway J. Lauwers P: Hemodynamic and hypotensive effects of long-term therapy with chlorothiazide. Circulation 21:21-27. 1960
6. de Carvalho JGR, Dunn FG. Lohmoller G. Frohlich ED: Hemodynamic correlates of prolonged thiazide therapy: Comparison of responders and nonresponders. Clin Pharmacol Titer 22:875-880, 1977
7. Leth A: Changes in plasma and ECF volumes in patients with essential hypertension during long-term treatment with hydrochlorothiazide. Circulation 42:479-485. 1970
8. Nustad K: Localization of kininogenasc in the rat kidney. Br J Pharmacol 19:87-98. 1970
9. Margolius HS. Cellar R. Pisano JJ: Altered urinary kallikrein excretion in human hypertension. Lancet 2:1063-1065. 1971
10. Margolius HS. Horwitz D. Pisano JJ. Reiser HR: Urinary kallikrein excretion in hypertensive man: Relationship to sodium intake and sodium retaining steroids. Circ Res 35:820-825. 1974
11. Levy SB. Lilley JJ. Frigon RP. Stone RA: Urinary kallikrein and plasma renin activity as determinants of renal blood flow: The influence of race and dietary sodium intake. J Clin Invest 60:129-138. 1977
12. Mitas JA. Holle R. Levy SB. Stone RA: Racial analysis of the volume-renin relationship in human hypertension. Arch Intern Med 139:157-160. 1979
13. Cole BR. Giangiacomo J. Ingelfinger JR. Robison AM: Measurement of renal function without urine collection: A critical evaluation of the constant-infusion technique for determinations of inulin and para-aminohippurate. N Engl J Med 287:1109-1114. 1972
14. Haber E. Koerner T. Page LB. Kliman B. Purnode A: Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Melah 29:1349-1355. 1969
15. Sampson EJ. Derek DD. Demers LM: Comparison of two radioimmunoassay kits for aldosterone determination. Clin Biocliem 9:216-221. 1976
16. Sullivan JM. Adams DF. Hollenberg NK: Β-Adrenergic blockade in essential hypertension. Reduced renin release despite renal vasoconstriction. Circ Res 39:532-536. 1967
17. Bliss CI: Statistics in Biology. McGraw-Hill. New York. 1967
18. Webster ME, Pierce JV: The nature of kallidins released from human plasma by kallikreins and other enzymes. Ann NY Acad Sei 104:91-105. 1963
19. Seino M. Aber K. Irokawa N. Ito T. Yasajima M. Sakurai Y. Chiba S. Saito K. Ritz K. Kusaka T. Miyazaki S. Yoshinga K: Effect of furosemide on urinary kallikrein excretion in patients with essential hypertension. Tohokn J Exp Med 124:197-203. 1978
20. O'Connor DT. Preston RA. Mitas JA. Frigon RP. Stone RA: Urinary kallikrein activity and renal vascular resistance in the antihypertensive response to thiazide diuretics. Hypertension (in press)
21. Nielson CK. Arrigoni-Martelli E: Effects on rat urinary kallikrein excretion of bumetanide. bendroflumethiazide and hydralazine. Acta Pharmacol Toxicol 40:267-272.
22. Wong PY. Talamo RC. Williams GH. Colman RW: Response of the kallikrein-kinin and renin-angiotensin systems to saline infusion and upright posture. J Clin Invest 55:691-698. 1975
23. Vinci JM. Gill JR Jr. Bowden RE. Pisano JJ. Izzo JI. Jr. Radfar N. Raylor AA. Zusman RM. Bartter FC, Reiser HR: The kallikrein-kinin system in Banter's syndrome and its response to prostaglandin synthetase inhibition. J Clin Invest 61:1671-1682. 1978
24. Vinci JM. Zusman RM. Izzo JL. Bowden RE. Horwitz D. Pisano JJ. Keiser HR: Human urinary and plasma kinins: Relationship to sodium-retaining steroids and plasma renin activity. Circ Res 44:228-237. 1979
25. Mersey JH, Williams GH. Emanuel R. Dluhy RG. Wong PY. Moore TJ: Plasma bradykinin levels and urinary kallikrein excretion in normal renin essential hypertension. J Clin Endocrinol Mctah 48:642-647. 1979
26. Bourland WE. Day AK. Williamson HE: The role of the kidney in the early nondiuretic action of furosemide to reduce elevated left atrial pressure in the hypervolemic dog. J Pharmacol Exp Titer 202:221-229. 1977
27. Gilmore E. Weil J. Chidsey C: Treatment of essential hypertension with a new vasodilator in combination with beta-adrenergic blockage. N Engl J Med 282:521-527. 1970
28. Horton R: Laboratory determinations of aldosterone and their clinical significance. Am J Clin Pathol 54:297-302. 1970